AI assistant
Teva Pharmaceutical Industries Ltd. — Director's Dealing 2022
Mar 8, 2022
7082_dirs_2022-03-08_43b6463f-4023-43b6-ad55-5327078c1114.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK: 0000818686
Period of Report: 2022-03-04
Reporting Person: Kalif Eliyahu Sharon (EVP, Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-03-05 | Ordinary Shares | M | 21387 | — | Acquired | 64876 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-03-04 | Restricted Share Units | $ | A | 134048 | Acquired | Ordinary Shares (134048) | Direct | |
| 2022-03-05 | Restricted Share Units | $ | M | 21387 | Disposed | Ordinary Shares (21387) | Direct |
Footnotes
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources
and Compensation Committee, the cash value of one ordinary share.
F3: Restricted share units were granted on March 4, 2022, with 33,512 vesting on each of March 4, 2023, March 4, 2024, March 4, 2025 and March 4, 2026.
F4: Restricted share units were granted on March 5, 2021, with 21,387 vesting on each of March 5, 2022, March 5, 2023, March 5, 2024 and 21,390
vesting on March 5, 2025.